<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0604257179
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2025
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Imjudo
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TREMELIMUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Concentrate for solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6697.25
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="VETTER PHARMA-FERTIGUNG, GMBH &amp; CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            VETTER PHARMA-FERTIGUNG, GMBH & CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L01-ANTINEOPLASTIC AGENTS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>IMJUDO is an anti-cancer medicine. It contains the active substance tremelimumab, which is a type of medicine called a <em>monoclonal antibody. </em>This medicine is designed to recognise a specific target substance in the body. IMJUDO works by helping your immune system fight your cancer.</p><p>&nbsp;</p><p>IMJUDO in combination with durvalumab is used to treat a type of liver cancer, called advanced or unresectable hepatocellular carcinoma (HCC). It is used when your HCC:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cannot be removed by surgery (unresectable), and</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; may have spread within your liver or to other parts of the body.</p><p>&nbsp;</p><p>As Imjudo will be given in combination with other anti-cancer medicines, it is important that you also read the package leaflet for these other medicines. If you have any questions about how Imjudo works or why this medicine has been prescribed for you, ask your doctor or pharmacist</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>You should not be given </strong><strong>IMJUDO</strong></p><p>if you are allergic to tremelimumab or any of the other ingredients of this medicine (listed in section 6). Talk to your doctor<strong> </strong>if you are not sure.</p><p>&nbsp;</p><p><strong>Warnings and precautions </strong></p><p><strong>Talk to your doctor before you are given IMJUDO if:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an autoimmune disease (an illness where the body&rsquo;s immune system attacks its own cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have had an organ transplant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have lung or breathing problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have liver problems.</p><p>&nbsp;</p><p><strong>Talk to your doctor</strong> before you are given IMJUDO if any of these could apply to you.</p><p>&nbsp;</p><p>When you are given IMJUDO, you can have some <strong>serious side effects</strong>.</p><p>&nbsp;</p><p>Your doctor may give you other medicines that prevent more severe complications and to help reduce your symptoms. Your doctor may delay the next dose of IMJUDO or stop your treatment with IMJUDO. <strong>Talk to your doctor straight away</strong> if you get any of the following side effects:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;New or worsening cough; shortness of breath; chest pain (may be signs of <strong>lung</strong> inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea) or vomiting; feeling less hungry; pain on the right side of your stomach; yellowing of skin or whites of eyes; drowsiness; dark urine or bleeding or bruising more easily than normal may be signs of <strong>liver </strong>inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea or more bowel movements than usual; stools that are black, tarry or sticky with blood or mucus; severe stomach pain or tenderness (may be signs of <strong>bowel</strong> inflammation, or a hole in the bowel)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart rate; extreme tiredness; weight gain or weight loss; dizziness or fainting; hair loss; feeling cold; constipation; headaches that will not go away or unusual headaches (may be signs of <strong>glands </strong>being inflamed,<strong> </strong>especially the thyroid, adrenal, pituitary or pancreas)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling more hungry or thirsty than usual; passing urine more often than usual; high blood sugar; fast and deep breathing; confusion; a sweet smell to your breath; a sweet or metallic taste in your mouth or a different odour to your urine or sweat (may be signs of <strong>diabetes</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in the amount of urine you pass (may be sign of<strong> kidney </strong>inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash; itching; skin blistering or ulcers in the mouth or on other moist surfaces (may be signs of<strong> skin </strong>inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain; shortness of breath; irregular heartbeat (may be signs of<strong> heart muscle </strong>inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle pain or weakness or rapid tiring of the muscles (may be signs of<strong> </strong>inflammation<strong> </strong>or other problems of the <strong>muscles</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chills or shaking, itching or rash, flushing, shortness of breath or wheezing, dizziness or fever (may be signs of<strong> infusion-related reactions)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; seizures; neck stiffness; headache; fever, chills; vomiting; eye sensitivity to light; confusion and sleepiness (may be signs of inflammation of the <strong>brain</strong> or the membrane around the brain and <strong>spinal cord)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain; weakness and paralysis in the hands, feet or arms (may be signs of inflammation of the <strong>nerves</strong>, Guillain-Barr&eacute; syndrome)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding (from the nose or gums) and/or bruising (may be signs of<strong> low blood platelets)</strong>.</p><p>&nbsp;</p><p><strong>Talk to &nbsp;your doctor straight away</strong> if you have any of the symptoms listed above.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>IMJUDO should not be given to children and adolescents below 18 years of age as it has not been studied in these patients.</p><p>&nbsp;</p><p><strong>Other medicines and IMJUDO</strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines. This includes herbal medicines and medicines obtained without a prescription.</p><p>&nbsp;</p><p><strong>Pregnancy and fertility</strong></p><p>This medicine is <strong>not recommended during pregnancy</strong>. Tell your doctor if you are pregnant, think you may be pregnant or are planning to have a baby.<strong> </strong>If you are a woman who could become pregnant, you must use effective contraception while you are being treated with IMJUDO and for at least 3 months after your last dose.</p><p>&nbsp;</p><p><strong>Breast‑feeding</strong></p><p>Tell your doctor if you are breast‑feeding. It is not known if IMJUDO passes into human breast milk. You may be advised to not breast-feed during treatment and for at least 3 months after your last dose.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>IMJUDO is not likely to affect your driving or use of machines. However, if you have side effects that affect your ability to concentrate and react, be careful when driving or operating machines.</p><p>&nbsp;</p><p><strong>IMJUDO has a low sodium content </strong></p><p>IMJUDO contains less than 1&nbsp;mmol sodium (23&nbsp;mg) in each dose, that is to say essentially sodium-</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>IMJUDO will be given to you in a hospital or clinic under the supervision of an experienced doctor. It is given in combination with durvalumab and chemotherapy.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>The recommended dose</strong> for advanced or unresectable hepatocellular carcinoma (HCC):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you weigh 40&nbsp;kg or more, the dose is 300&nbsp;mg as a one-time single dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you weigh less than 40&nbsp;kg, the dose will be 4&nbsp;mg per kg of your body weight.</p><p>&nbsp;</p><p>Your doctor will give you IMJUDO as a drip into your vein (infusion) lasting about 1 hour.</p><p>&nbsp;</p><p>You will usually have a total of 5<strong>&nbsp;</strong>doses of Imjudo. The first 4<strong> </strong>doses are given in week 1, 4, 7 and<strong> </strong>10. The fifth dose is usually then given 6<strong>&nbsp;</strong>weeks later, in week<strong> </strong>16. Your doctor will decide exactly how many treatments you need.</p><p>&nbsp;</p><p>When IMJUDO is given in combination with durvalumab for your liver cancer, you will be given IMJUDO first, then durvalumab.</p><p>&nbsp;</p><p><strong>If you miss an appointment</strong></p><p>It is very important that you do not miss a dose of this medicine. If you miss an appointment, <strong>call your doctor straight away </strong>to reschedule your appointment.</p><p>&nbsp;</p><p>If you have any further questions about your treatment, ask your doctor.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>When you get IMJUDO, you can have some serious side effects.<strong> See section&nbsp;2</strong> for a detailed list of these<strong>.</strong></p><p>&nbsp;</p><p><strong>Talk to your doctor straight away</strong> if you get any of the following side effects that have been reported in a clinical study with patients receiving IMJUDO in combination with durvalumab.</p><p>&nbsp;</p><p>The following side effects have been reported in clinical trials in patients taking IMJUDO in combination with durvalumab:</p><p>&nbsp;</p><p><strong>Very common (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp; Infections of the upper respiratory tract</p><p>&middot;&nbsp;&nbsp; lung infection (pneumonia)</p><p>&middot;&nbsp;&nbsp; low number of red blood cells</p><p>&middot;&nbsp;&nbsp; low number of white blood cells</p><p>&middot;&nbsp;&nbsp; low number of platelets</p><p>&middot;&nbsp;&nbsp; underactive thyroid gland that can cause tiredness or weight gain</p><p>&middot;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp; abnormal liver tests (aspartate aminotransferase increased; alanine aminotransferase increased)</p><p>&middot;&nbsp;&nbsp; hair loss</p><p>&middot;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp; itchiness</p><p>&middot;&nbsp;&nbsp; joint pain (arthralgia)</p><p>&middot;&nbsp;&nbsp; feeling tired or weak</p><p>&middot;&nbsp;&nbsp; fever</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp; flu-like illness</p><p>&middot;&nbsp;&nbsp; fungal infection in the mouth</p><p>&middot;&nbsp;&nbsp; low number of white blood cells with signs of fever</p><p>&middot;&nbsp;&nbsp; low number of red blood cells, white blood cells, and platelets (pancytopenia)</p><p>&middot;&nbsp;&nbsp; overactive thyroid gland that can cause fast heart rate or weight loss</p><p>&middot;&nbsp;&nbsp; decreased levels of hormones produced by the adrenal glands that can cause tiredness</p><p>&middot;&nbsp;&nbsp; underactive pituitary gland; inflammation of pituitary gland</p><p>&middot;&nbsp;&nbsp; inflammation of the thyroid gland (thyroiditis)</p><p>&middot;&nbsp;&nbsp; inflammation of the lungs (pneumonitis)</p><p>&middot;&nbsp;&nbsp; hoarse voice (dysphonia)</p><p>&middot;&nbsp;&nbsp; inflammation of the mouth or lips</p><p>&middot;&nbsp;&nbsp; abnormal pancreas function tests</p><p>&middot;&nbsp;&nbsp; abnormal pancreas function tests</p><p>&middot;&nbsp;&nbsp; inflammation of the gut or intestine (colitis)</p><p>&middot;&nbsp;&nbsp; inflammation of the pancreas (pancreatitis)</p><p>&middot;&nbsp;&nbsp; inflammation of the liver that can cause nausea or feeling less hungry (hepatitis)</p><p>&middot;&nbsp;&nbsp; muscle pain (myalgia)</p><p>&middot;&nbsp;&nbsp; abnormal kidney function test (blood creatinine increased)</p><p>&middot;&nbsp;&nbsp; painful urination (dysuria)</p><p>&middot;&nbsp;&nbsp; swelling of legs (oedema peripheral)</p><p>&middot;&nbsp;&nbsp; reaction to the infusion of the medicine that can cause fever or flushing</p><p>&nbsp;</p><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp; tooth and mouth soft tissue infections</p><p>&middot;&nbsp;&nbsp; low number of platelets with signs of excessive bleeding and bruising (immune thrombocytopenia)</p><p>&middot;&nbsp;&nbsp; diabetes insipidus</p><p>&middot;&nbsp;&nbsp; type 1 diabetes mellitus</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; inflammation of the heart (myocarditis)</p><p>&middot;&nbsp;&nbsp; scarring of lung tissue</p><p>&middot;&nbsp;&nbsp; blistering of the skin</p><p>&middot;&nbsp;&nbsp; inflammation of the muscles (myositis)</p><p>&middot;&nbsp;&nbsp; inflammation of the muscles and vessels</p><p>&middot;&nbsp;&nbsp; inflammation of the kidneys (nephritis) that can decrease the amount of your urine</p><p>&nbsp;</p><p><strong>Other side effects that have been reported with frequency not known (cannot be estimated from the available data)</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; a condition in which the muscles become weak and there is a rapid fatigue of the muscles (myasthenia gravis)</p><p>&middot;&nbsp;&nbsp; inflammation of the nerves (Guillain-Barr&eacute; syndrome)</p><p>&middot;&nbsp;&nbsp; hole in the bowel (intestinal perforation)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>IMJUDO will be given to you in a hospital or clinic and the healthcare professional will be responsible for its storage.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2&nbsp;&deg;C&nbsp;-&nbsp;8&nbsp;&deg;C).</p><p>Do not freeze.</p><p>Store in the original package in order to protect from light.</p><p>Do not use if this medicine is cloudy, discoloured or contains visible particles.</p><p>Do not store any unused portion of the infusion solution for re‑use. Any unused medicine or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is tremelimumab.</p><p>&nbsp;</p><p>Each&nbsp;ml of concentrate for solution for infusion contains&nbsp;20&nbsp;mg of tremelimumab.</p><p>&nbsp;</p><p>One vial contains either 300&nbsp;mg of tremelimumab in 15&nbsp;ml of concentrate or 25&nbsp;mg of tremelimumab in 1.25&nbsp;ml of concentrate.</p><p>&nbsp;</p><p>The other ingredients are: histidine, histidine hydrochloride monohydrate, trehalose dihydrate, disodium edetate dihydrate (see section 2 &ldquo;IMJUDO has a low sodium content&rdquo;), polysorbate 80 and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                IMJUDO concentrate for solution for infusion (sterile concentrate) is a preservative-free, clear to slightly opalescent, colourless to slightly yellow solution, free from visible particles.
	
It is available in packs containing either 1 glass vial of 1.25 ml of concentrate or 1 glass vial of 15 ml of concentrate.

Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>AstraZeneca AB</p><p>SE‑151 85 S&ouml;dert&auml;lje</p><p>Sweden</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Vetter Pharma-Fertigung GmbH &amp; Co. KG</p><p>Mooswiesen 2</p><p>88214 Ravensburg,</p><p>Germany</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Jun 2024.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو إمجودو </strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">إمجودو هو مستضد مرتبط بالخلايا اللمفاوية التائية القاتلة 4 (CTLA-4) يحجب الجسم المضاد أحادي النسيلة IgG2 البشري، ويتم إنتاجه بواسطة تقنية الحمض النووي المؤتلف في مزرعة الخلية المعلقة NS0 وله وزن جزيئي 149 كيلو دالتون.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong>إمجودو هو دواء مضاد للسرطان. يحتوي على المادة الفعالة تريميليموماب ، وهو نوع من الأدوية يسمى الجسم المضاد أحادي النسيلة. تم تصميم هذا الدواء للتعرف على مادة مستهدفة معينة في الجسم. يعمل إمجودو من خلال مساعدة جهازك المناعي على محاربة السرطان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يستخدم إمجودو بالاشتراك مع دورفالوماب لعلاج نوع من سرطان الكبد ، يسمى سرطان الخلايا الكبدية المتقدمة أو غير القابلة للاستئصال (HCC). يتم استخدامه عندما:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يمكن إزالته عن طريق الجراحة (غير قابل للقطع) ، و</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد ينتشر داخل الكبد أو إلى أجزاء أخرى من الجسم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نظرًا لأنه سيتم إعطاء إمجودو مع أدوية أخرى مضادة للسرطان ، فمن المهم أن تقرأ أيضًا النشرة لهذه الأدوية الأخرى. إذا كان لديك أي أسئلة حول كيفية عمل إمجودو أو لماذا تم وصف هذا الدواء لك ، اسأل طبيبك أو الصيدلي</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا يجب أن تتلقى إمجودو</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية لتريميليموماب أو أي من المكونات الأخرى لهذا الدواء (مذكورة في القسم&nbsp;6). تحدَّث إلى طبيبك أو ممرضتك إذا لم تكن متأكّدًا من ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL"><strong>تحدَّث إلى طبيبك أو ممرضتك قبل تلقي إمجودو إذا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مرض مناعي ذاتي (مرض يهاجم فيه جهاز المناعة في الجسم خلاياه)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أجريت لك عملية زرع عضو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل في الرئة أو التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل في الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك قبل إعطائك<strong> </strong>إمجودو إذا كان أي من هذه الأعراض تنطبق عليك<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يتم إعطاؤك<strong> </strong>إمجودو ، يمكن أن يكون لديك بعض الآثار الجانبية الخطيرة<strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يعطيك طبيبك أدوية أخرى تمنع حدوث مضاعفات أكثر خطورة وتساعد في تقليل الأعراض. قد يؤخر طبيبك الجرعة التالية من إمجودو أو يوقف علاجك بـ إمجودو. تحدث إلى طبيبك على الفور إذا كنت تعاني من أي من الآثار الجانبية التالية<strong>:</strong><strong> </strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال جديد أو متفاقم. ضيق في التنفس؛ ألم في الصدر (قد يكون من علامات التهاب الرئة).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالغثيان أو القيء. الشعور بجوع أقل ألم في الجانب الأيمن من معدتك. اصفرار الجلد أو بياض العين. النعاس. البول الداكن أو النزيف أو الكدمات بسهولة أكبر من المعتاد قد تكون علامات على التهاب الكبد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال أو حركات الأمعاء أكثر من المعتاد؛ براز أسود أو قطراني أو لزج بالدم أو المخاط ؛ ألم شديد في المعدة أو رقة (قد تكون علامات على التهاب الأمعاء ، أو ثقب في الأمعاء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة دقات القلب. التعب الشديد زيادة الوزن أو فقدان الوزن. الدوخة أو الإغماء. تساقط الشعر؛ الشعور بالبرد إمساك؛ صداع لا يختفي أو صداع غير عادي (قد يكون علامات على التهاب الغدد ، وخاصة الغدة الدرقية أو الغدة الكظرية أو الغدة النخامية أو البنكرياس)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالجوع أو العطش أكثر من المعتاد. التبول أكثر من المعتاد. ارتفاع نسبة السكر في الدم التنفس السريع والعميق ارتباك؛ رائحة حلوة في أنفاسك. طعم حلو أو معدني في فمك أو رائحة مختلفة عن البول أو العرق (قد تكون علامات لمرض السكري)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كمية البول التي تمر بها (قد تكون علامة على التهاب الكلى)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح؛ مثير للحكة؛ ظهور تقرحات أو تقرحات في الجلد في الفم أو على الأسطح الرطبة الأخرى (قد تكون علامات على التهاب الجلد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم صدر؛ ضيق في التنفس؛ عدم انتظام ضربات القلب (قد تكون علامات على التهاب عضلة القلب).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات أو ضعفها أو التعب السريع للعضلات (قد تكون علامات التهاب أو مشاكل أخرى في العضلات)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قشعريرة أو اهتزاز ، حكة أو طفح جلدي ، احمرار ، ضيق في التنفس أو أزيز ، دوخة أو حمى (قد تكون علامات على ردود الفعل المرتبطة بالتسريب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات؛ تصلب الرقبة صداع؛ حمى وقشعريرة القيء. حساسية العين للضوء. الارتباك والنعاس (قد تكون علامات على التهاب الدماغ أو الغشاء المحيط بالمخ والحبل الشوكي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم؛ ضعف وشلل في اليدين أو القدمين أو الذراعين (قد تكون علامات على التهاب الأعصاب ، متلازمة غيلان باريه)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف (من الأنف أو اللثة) و / أو كدمات (قد تكون علامات على انخفاض عدد الصفائح الدموية).</p><p dir="RTL">&nbsp;</p><p><strong>تحدث إلى طبيبك على الفور إذا كان لديك أي من الأعراض المذكورة أعلاه</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">لا ينبغي إعطاء إمجودو للأطفال والمراهقين الذين تقل أعمارهم عن 18 عامًا حيث لم يتم دراستها في هؤلاء المرضى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وإمجودو</strong></p><p dir="RTL"><strong>أخبر مقدم الرعاية الصحية المتابع لك بجميع الأدوية التي تتلقاها</strong>، بما في ذلك الأدوية التي تؤخَذ بوصفة طبية ومن دون وصفة طبية، والفيتامينات، والمكملات العشبية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية </strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL"><strong><u>الحمل</u></strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">لا ينصح بهذا الدواء أثناء الحمل. أخبري طبيبك إذا كنت حاملاً أو تعتقدين أنك حامل أو تخططين لإنجاب طفل. إذا كنت امرأة يمكن أن تصبح حاملاً ، فيجب عليك استخدام وسيلة فعالة لمنع الحمل أثناء علاجك بـ <strong>إمجودو</strong> ولمدة 3 أشهر على الأقل بعد آخر جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong><u>الرضاعة الطبيعية</u></strong></p><p dir="RTL"><strong><u>&nbsp;</u></strong></p><p dir="RTL">أخبر طبيبك إذا كنت ترضعين. من غير المعروف ما إذا كان إمجودو ينتقل إلى حليب الثدي البشري. قد يُنصح بعدم الرضاعة الطبيعية أثناء العلاج ولمدة 3 أشهر على الأقل بعد آخر جرعة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p>&nbsp;</p><p dir="RTL">من غير المحتمل أن تؤثر إمجودو على قيادتك أو استخدامك للآلات. ومع ذلك ، إذا كانت لديك آثار جانبية تؤثر على قدرتك على التركيز والتفاعل ، فاحذر عند القيادة أو تشغيل الآلات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك إمجودو في مستشفى أو عيادة تحت إشراف طبيب متمرس. يتم إعطاؤه بالاشتراك مع دورفالوماب والعلاج الكيميائي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة الموصى بها لسرطان الخلايا الكبدية المتقدم أو غير القابل للاكتشاف (HCC):</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا كان وزنك 40 كجم أو أكثر ، تكون الجرعة 300 مجم كجرعة واحدة لمرة واحدة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; إذا كان وزنك أقل من 40 كجم ، فستكون الجرعة 4 مجم لكل كجم من وزن جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سوف يعطيك طبيبك إمجودو على شكل قطرة في الوريد (التسريب) لمدة ساعة تقريبًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عادة ما يكون لديك ما مجموعه 5 جرعات من إمجودو. يتم إعطاء الجرعات الأربع الأولى في الأسبوع 1 و 4 و 7 و 10. وتعطى الجرعة الخامسة عادة بعد 6 أسابيع ، في الأسبوع 16. سيقرر طبيبك بالضبط عدد العلاجات التي تحتاجها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يتم إعطاء إمجودو بالاشتراك مع دورفالوماب لسرطان الكبد لديك ، سيتم إعطاؤك إمجودو أولاً ، ثم دورفالوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا فاتك الموعد</strong></p><p dir="RTL">من المهم جدًا ألا تفوت جرعة من هذا الدواء. إذا فاتك موعد ، <strong>اتصل بطبيبك على الفور لإعادة تحديد موعدك</strong>.</p><p dir="RTL">إذا كانت لديك أي أسئلة أخرى حول علاجك ، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية ، يمكن أن يسبب هذا الدواء آثارًا جانبية ، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما تحصل على إمجودو ، يمكن أن يكون لديك بعض الآثار الجانبية الخطيرة. انظر القسم 2 للحصول على قائمة مفصلة بهذه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك على الفور إذا كنت تعاني من أي من الآثار الجانبية التالية التي تم الإبلاغ عنها في دراسة سريرية مع المرضى الذين يتلقون إمجودو بالاشتراك مع دورفالوماب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن الآثار الجانبية التالية في التجارب السريرية في المرضى الذين يتناولون إمجودو بالاشتراك مع دورفالوماب:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة للغاية</strong> (قد تُصيب أكثر من شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهابات الجهاز التنفسي العلوي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الرئة (الالتهاب الرئوي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة عدد خلايا الدم الحمراء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة عدد خلايا الدم البيضاء</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة عدد الصفائح الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور الغدة الدرقية الذي يمكن أن يسبب التعب أو زيادة الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبارات الكبد غير الطبيعية (زيادة الأسبارتات aminotransferase ؛ زيادة ألانين aminotransferase)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تساقط الشعر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل (arthralgia)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب أو الضعف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة</strong> (قد تصيب شخصًا واحدًا على الأكثر من كل 10 أشخاص)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مرض شبيه بالإنفلونزا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;عدوى فطرية في الفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض عدد خلايا الدم البيضاء مع ظهور علامات الحمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض عدد خلايا الدم الحمراء وخلايا الدم البيضاء والصفائح الدموية (قلة الكريات الشاملة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;فرط نشاط الغدة الدرقية الذي يمكن أن يسبب سرعة دقات القلب أو فقدان الوزن</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;انخفاض مستويات الهرمونات التي تفرزها الغدد الكظرية التي يمكن أن تسبب التعب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;الغدة النخامية غير النشطة. التهاب الغدة النخامية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الغدة الدرقية (التهاب الغدة الدرقية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الرئتين (التهاب رئوي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;صوت أجش (بحة الصوت)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الفم أو الشفتين</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبارات وظائف البنكرياس غير الطبيعية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اختبارات وظائف البنكرياس غير الطبيعية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الأمعاء أو الأمعاء (التهاب القولون)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب البنكرياس (التهاب البنكرياس)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التهاب الكبد الذي يمكن أن يسبب الغثيان أو الشعور بجوع أقل (التهاب الكبد)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;ألم عضلي (ألم عضلي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;اختلال في اختبار وظائف الكلى (زيادة الكرياتينين في الدم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;التبول المؤلم (عسر البول)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;تورم الساقين (وذمة محيطية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;رد فعل على تسريب الدواء يمكن أن يسبب الحمى أو الاحمرار</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب شخصًا واحدًا من كل 100 أشخاص)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; التهابات الأنسجة الرخوة الأسنان والفم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; انخفاض عدد الصفائح الدموية مع علامات النزيف والكدمات (قلة الصفيحات المناعية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; مرض السكري الكاذب</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; داء السكري من النوع الأول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; التهاب القلب (التهاب عضلة القلب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; تندب أنسجة الرئة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; ظهور تقرحات في الجلد</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; التهاب العضلات (التهاب العضل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; التهاب العضلات والأوعية الدموية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp; التهاب الكلى (التهاب الكلية) الذي يمكن أن يقلل من كمية البول</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp; <strong>الآثار الجانبية الأخرى التي تم الإبلاغ عنها بتواتر غير معروف (لا يمكن تقديرها من البيانات المتاحة)</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; حالة تضعف فيها العضلات ويحدث إجهاد سريع للعضلات (الوهن العضلي الوبيل)</p><p dir="RTL">&bull; التهاب الأعصاب (متلازمة غيلان باريه)</p><p dir="RTL">&bull; ثقب في الأمعاء (انثقاب معوي)داء السكري من النوع الأول</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيتم إعطاؤك إمجودو في مستشفى أو عيادة وسيكون أخصائي الرعاية الصحية مسؤولاً عن تخزينه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">احفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على ملصق الكرتون والقنينة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من نفس الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحفظ في الثلاجة (2 درجة مئوية - 8 درجة مئوية).</p><p dir="RTL">لا تجمده.</p><p dir="RTL">يجب التخزين في العلبة الأصلية لحمايته من الضوء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء إذا كان عكرًا أو متغير اللون أو يحتوي على جزيئات مرئية.</p><p>&nbsp;</p><p dir="RTL">لا تقم بتخزين أي جزء غير مستخدم من محلول التسريب لإعادة استخدامه. يجب التخلص من أي دواء أو نفايات غير مستخدمة وفقًا للمتطلبات المحلية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات إمجودو </strong></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><strong>المادة الفعالة</strong> هي تريميليموماب-أكتل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong> هي: أديتات ثنائي الصوديوم، هيستيدين، وأحادي هيدرات هيدوكلوريد الهيستيدين، وبوليسوربات 80&rlm;، وتريهالوز، وماء للحقن.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل دواء إمجودو ومحتويات العبوة</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">حقن إمجودو (تريميليموماب-أكتل) عبارة عن محلول لونه شفاف إلى غائم قليلًا، عديم اللون إلى أصفر قليلًا يأتي في علبة كرتونية تحتوي على قنينة أحادية الجرعة بالتركيزات التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25 مجم/1.25 مل (20 مجم/مل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 300 مجم/15 مل (20 مجم/مل)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق </strong></p><p dir="RTL">AstraZeneca AB</p><p dir="RTL">SE-151 85</p><p dir="RTL">S&ouml;dert&auml;lje</p><p dir="RTL">السويد</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>جهة التصنيع</strong></p><p dir="RTL">Vetter Pharma-Fertigung GmbH &amp; Co. KG</p><p dir="RTL">Mooswiesen 2</p><p dir="RTL">88214 Ravensburg,</p><p dir="RTL">ألمانيا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	تمت آخر مراجعة لهذه النشرة في يونيو 2024 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                IMJUDO 20 mg/ml concentrate for solution for infusion.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each mL of concentrate for solution for infusion contains 20 mg of tremelimumab.
One vial of 1.25 ml of concentrate contains 25 mg of tremelimumab. 
One vial of 15 ml of concentrate contains 300 mg of tremelimumab. 

Tremelimumab is a human anti-CTLA-4 immunoglobulin G2 IgG2a monoclonal antibody produced in murine myeloma cells by recombinant DNA technology.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Concentrate for solution for infusion (sterile concentrate).

Clear to slightly opalescent, colourless to slightly yellow solution, free from or practically free from visible particles. The solution has a pH of approximately 5.5 and an osmolality of approximately 285 mOsm/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Imjudo in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC) who have not received prior treatment with a PD-1/PD-L1 inhibitor.</p><p>&nbsp;</p><p><strong>This indication is approved with commitment to provide verification and description of clinical benefit in a confirmatory trial</strong></p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment must be initiated and supervised by a physician experienced in the treatment of cancer.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended dose of IMJUDO is presented in Table 1. IMJUDO is administered as an intravenous infusion over 1&nbsp;hour.</p><p><strong>&nbsp;</strong></p><p><strong>Table 1: Recommended dose of IMJUDO</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:603px"><thead><tr><td style="vertical-align:top"><p><strong>Indication</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Recommended IMJUDO dosage</strong>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Duration of Therapy</strong>&nbsp;</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Advanced or unresectable HCC</p></td><td style="vertical-align:top"><p>IMJUDO 300&nbsp;mg<sup>a</sup><strong> </strong>as a single dose administered in combination with durvalumab 1500&nbsp;mg<sup>a</sup> at Cycle 1/Day 1,</p><p>followed by durvalumab monotherapy every 4 weeks</p></td><td style="vertical-align:top"><p>Until disease progression or unacceptable toxicity</p></td></tr></tbody></table><p><sup>a </sup>For IMJUDO, HCC patients with a body weight of 40&nbsp;kg or less must receive weight-based dosing, equivalent to IMJUDO 4&nbsp;mg/kg until weight is greater than 40&nbsp;kg. For durvalumab, patients with a body weight of 30&nbsp;kg or less must receive weight-based dosing, equivalent to durvalumab 20&nbsp;mg/kg until weight is greater than 30&nbsp;kg.</p><p>Dose escalation or reduction is not recommended during treatment with IMJUDO in combination with durvalumab. Treatment withholding or discontinuation may be required based on individual safety and tolerability.</p><p>&nbsp;</p><p>Guidelines for management of immune-mediated adverse reactions are described in Table 2 (see section 4.4). Refer also to the summary of product characteristics (SmPC) for durvalumab.</p><p><strong>&nbsp;</strong></p><p><strong>Table 2. Treatment modifications and management recommendations for IMJUDO in combination with durvalumab</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Adverse reactions</strong></p></td><td><p><strong>Severity</strong><sup>a</sup></p></td><td><p><strong>Treatment modification</strong></p></td><td><p><strong>Corticosteroid treatment unless otherwise specified</strong><sup>b</sup></p></td></tr></thead><tbody><tr><td rowspan="2"><p>Immune-mediated pneumonitis/interstitial lung disease</p></td><td><p>Grade 2</p></td><td><p>Withhold dose<sup>c</sup></p></td><td rowspan="2"><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>Grade 3 or 4</p></td><td><p>Permanently discontinue</p></td></tr><tr><td rowspan="4"><p>Immune-mediated hepatitis</p></td><td><p>ALT or AST &gt;&nbsp;3&nbsp;-&nbsp;&le;&nbsp;5&nbsp;x&nbsp;ULN or total bilirubin &gt;&nbsp;1.5&nbsp;-&nbsp;&le;&nbsp;3&nbsp;x&nbsp;ULN</p></td><td><p>Withhold dose<sup>c</sup></p></td><td rowspan="4"><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>ALT or AST &gt;&nbsp;5&nbsp;-&nbsp;&le;&nbsp;10&nbsp;x&nbsp;ULN</p></td><td><p>Withhold durvalumab and permanently discontinue IMJUDO (where appropriate)</p></td></tr><tr><td><p>Concurrent ALT or AST &gt;&nbsp;3&nbsp;x&nbsp;ULN and total bilirubin &gt;&nbsp;2&nbsp;x&nbsp;ULN<sup>d</sup></p></td><td rowspan="2"><p>Permanently discontinue</p></td></tr><tr><td><p>ALT or AST &gt;&nbsp;10&nbsp;x&nbsp;ULN or total bilirubin &gt;&nbsp;3&nbsp;x&nbsp;ULN</p></td></tr><tr><td rowspan="3"><p>Immune-mediated hepatitis in HCC (or secondary tumour involvement of the liver&nbsp;with abnormal baseline values)<sup>e</sup></p><p>&nbsp;</p></td><td><p>ALT or AST &gt;&nbsp;2.5&nbsp;-&nbsp;&le;&nbsp;5&nbsp;x&nbsp;BLV and &le;&nbsp;20&nbsp;x&nbsp;ULN</p></td><td><p>Withhold dose<sup>c</sup></p></td><td rowspan="3"><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>ALT or AST &gt;&nbsp;5&nbsp;-&nbsp;7 x BLV and &le;&nbsp;20&nbsp;x&nbsp;ULN</p><p>or</p><p>concurrent ALT or AST 2.5&nbsp;-&nbsp;5&nbsp;x&nbsp;BLV and &le;&nbsp;20&nbsp;x&nbsp;ULN and total bilirubin &gt;&nbsp;1.5&nbsp;-&nbsp;&lt;&nbsp;2&nbsp;x&nbsp;ULN<sup>d</sup></p></td><td><p>Withhold durvalumab and permanently discontinue IMJUDO (where appropriate)</p></td></tr><tr><td><p>ALT or AST &gt;&nbsp;7&nbsp;x&nbsp;BLV or &gt;&nbsp;20&nbsp;x&nbsp;ULN</p><p>whichever occurs first</p><p>or bilirubin &gt;&nbsp;3&nbsp;x&nbsp;ULN</p></td><td><p>Permanently discontinue</p></td></tr><tr><td rowspan="3"><p>Immune-mediated colitis or diarrhoea</p></td><td><p>Grade 2</p></td><td><p>Withhold dose<sup>c</sup></p></td><td rowspan="2"><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>Grade 3 or 4</p></td><td><p>Permanently discontinue</p></td></tr><tr><td><p>Intestinal perforation of ANY grade</p></td><td><p>Permanently discontinue</p></td><td><p>Consult a surgeon immediately if an intestinal perforation is suspected</p></td></tr><tr><td><p>Immune-mediated hyperthyroidism, thyroiditis</p></td><td><p>Grade 2-4</p></td><td><p>Withhold dose until clinically stable</p></td><td><p>Symptomatic management</p></td></tr><tr><td><p>Immune-mediated hypothyroidism</p></td><td><p>Grade 2-4</p></td><td><p>No changes</p></td><td><p>Initiate thyroid hormone replacement as clinically indicated</p></td></tr><tr><td><p>Immune-mediated adrenal insufficiency,<br />hypophysitis/hypopituitarism</p></td><td><p>Grade 2-4</p></td><td><p>Withhold dose until clinically stable</p></td><td><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper and hormone replacement as clinically indicated</p></td></tr><tr><td><p>Immune-mediated Type 1 diabetes mellitus&nbsp;</p></td><td><p>Grade 2-4</p></td><td><p>No changes</p></td><td><p>Initiate treatment with insulin as clinically indicated</p></td></tr><tr><td rowspan="2"><p>Immune-mediated nephritis</p></td><td><p>Grade 2 with serum creatinine &gt;&nbsp;1.5-3&nbsp;x&nbsp;(ULN or baseline)</p></td><td><p>Withhold dose<sup>c</sup></p></td><td rowspan="2"><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>Grade 3 with serum creatinine &gt;&nbsp;3&nbsp;x baseline or &gt;&nbsp;3-6&nbsp;x&nbsp;ULN; Grade 4 with serum creatinine &gt;&nbsp;6&nbsp;x&nbsp;ULN</p></td><td><p>Permanently discontinue</p></td></tr><tr><td rowspan="2"><p>Immune-mediated rash or dermatitis (including pemphigoid)&nbsp;</p></td><td><p>Grade 2 for &gt;&nbsp;1 week or Grade 3</p></td><td><p>Withhold dose<sup>c</sup></p></td><td rowspan="2"><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>Grade 4</p></td><td><p>Permanently discontinue</p></td></tr><tr><td><p>Immune-mediated myocarditis&nbsp;</p></td><td><p>Grade 2-4</p></td><td><p>Permanently discontinue</p></td><td><p>Initiate 2 to 4&nbsp;mg/kg/day prednisone or equivalent followed by a taper<sup>f</sup></p></td></tr><tr><td rowspan="2"><p>Immune-mediated myositis/polymyositis&nbsp;</p></td><td><p>Grade 2 or 3</p></td><td><p>Withhold dose<sup>c,g</sup></p></td><td rowspan="2"><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>Grade 4</p></td><td><p>Permanently discontinue</p></td></tr><tr><td rowspan="2"><p>Infusion-related reactions</p></td><td><p>Grade 1 or 2</p></td><td><p>Interrupt or slow the rate of infusion</p></td><td><p>May consider pre-medications for prophylaxis of subsequent infusion reactions</p></td></tr><tr><td><p>Grade 3 or 4</p></td><td><p>Permanently discontinue</p></td><td><p>Manage severe infusion-related reactions per institutional standard,<br />appropriate clinical practice guidelines and/or society guidelines</p></td></tr><tr><td><p>Immune-mediated myasthenia gravis&nbsp;</p></td><td><p>Grade 2-4</p><p><em>&nbsp;</em></p></td><td><p><s><sup>&nbsp;</sup></s></p><p>Permanently discontinue</p></td><td><p>Initiate 1 to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>Immune-mediated encephalitis</p></td><td><p>Grade 2-4</p></td><td><p>Permanently discontinue</p></td><td><p>Initiate 1&nbsp;to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td rowspan="2"><p>Other immune-mediated adverse reactions<sup>h &nbsp;&nbsp;</sup></p></td><td><p>Grade 2 or 3</p></td><td><p>Withhold dose<sup>c</sup></p></td><td rowspan="2"><p>Initiate 1&nbsp;to 2&nbsp;mg/kg/day prednisone or equivalent followed by a taper</p></td></tr><tr><td><p>Grade 4</p></td><td><p>Permanently discontinue</p></td></tr><tr><td rowspan="2"><p>Non-immune-mediated adverse reactions</p></td><td><p>Grade 2 and 3</p></td><td><p>Withhold dose until &le;&nbsp;Grade 1 or return to baseline</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Grade 4</p></td><td><p>Permanently discontinue<sup> i</sup></p></td><td><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup> Common Terminology Criteria for Adverse Events, version 4.03. ALT: alanine aminotransferase; AST: aspartate aminotransferase; ULN: upper limit of normal; BLV: baseline value.</p><p><sup>b</sup> Upon improvement to &le;&nbsp;Grade 1, corticosteroid taper should be initiated and continued over at least 1 month. Consider increasing dose of corticosteroids and/or using additional systemic immunosuppressants if there is worsening or no improvement.</p><p><sup>c</sup> After withholding, IMJUDO and/or durvalumab can be resumed within 12 weeks if the adverse reactions improved to &le;&nbsp;Grade 1 and the corticosteroid dose has been reduced to &le;&nbsp;10&nbsp;mg prednisone or equivalent per day. IMJUDO and durvalumab should be permanently discontinued for recurrent Grade 3 adverse reactions, as applicable.</p><p><sup>d</sup> For patients with alternative cause follow the recommendations for AST or ALT increases without concurrent bilirubin elevations.</p><p><sup>e</sup> If AST and ALT are less than or equal to ULN at baseline in patients with liver involvement, withhold or permanently discontinue durvalumab based on recommendations for hepatitis with no liver involvement.</p><p><sup>f</sup> If no improvement within 2 to 3 days despite corticosteroids, promptly start additional immunosuppressive therapy. Upon resolution (Grade 0), corticosteroid taper should be initiated and continued over at least 1 month.</p><p><sup>g</sup> Permanently discontinue IMJUDO and durvalumab if the adverse reaction does not resolve to &le;&nbsp;Grade 1 within 30 days or if there are signs of respiratory insufficiency.</p><p><sup>h</sup> Includes immune thrombocytopenia and pancreatitis.</p><p><sup>i</sup> With the exception of Grade 4 laboratory abnormalities, about which the decision to discontinue treatment should be based on accompanying clinical signs/symptoms and clinical judgment.</p><p>&nbsp;</p><p>For suspected immune-mediated adverse reactions, adequate evaluation should be performed to confirm aetiology or exclude alternate aetiologies.</p><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of IMJUDO in children and adolescents below 18 years of age have not been established. No data are available.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is required for elderly patients (&ge;&nbsp;65 years of age) (see section 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment of IMJUDO is recommended in patients with mild or moderate renal impairment. Data from patients with severe renal impairment are too limited to draw conclusions on this population (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment of IMJUDO is recommended for patients with mild or moderate hepatic impairment. IMJUDO has not been studied in patients with severe hepatic impairment (see section 5.2).</p><p><u>Method of administration</u></p><p>&nbsp;</p><p><em>Method of administration in </em><em>HCC</em>:</p><p>&nbsp;</p><p>IMJUDO is for intravenous use.</p><p>&nbsp;</p><p>Administer IMJUDO prior to durvalumab on the same day.</p><p>&nbsp;</p><p>IMJUDO and durvalumab are administered as separate intravenous infusions. Refer to the SmPC for durvalumab administration information.</p><p>&nbsp;</p><p>For instructions on dilution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the tradename and the batch number of the administered product should be clearly recorded.</p><p>&nbsp;</p><p><u>Immune‑mediated pneumonitis </u></p><p>Immune‑mediated pneumonitis or interstitial lung disease, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving &nbsp;tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for signs and symptoms of pneumonitis. Suspected pneumonitis should be confirmed with radiographic imaging and other infectious and disease-related aetiologies excluded, and managed as recommended in section 4.2.</p><p>&nbsp;</p><p><u>Immune‑mediated hepatitis</u></p><p>Immune-mediated hepatitis, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Monitor alanine aminotransferase, aspartate aminotransferase, total bilirubin, and alkaline phosphatase levels prior to initiation of treatment and prior to each subsequent infusion. Additional monitoring is to be considered based on clinical evaluation. Immune‑mediated hepatitis should be managed as recommended in section 4.2.</p><p>&nbsp;</p><p><u>Immune‑mediated colitis</u></p><p>Immune‑mediated colitis or diarrhoea, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Intestinal perforation and large intestine perforation were reported in patients receiving tremelimumab in combination with durvalumab. Patients should be monitored for signs and symptoms of colitis/diarrhoea and intestinal perforation and managed as recommended in section 4.2.</p><p>&nbsp;</p><p><u>Immune‑mediated endocrinopathies</u></p><p>&nbsp;</p><p><em><u>Immune-mediated hypothyroidism, hyperthyroidism and thyroiditis</u></em></p><p>Immune‑mediated hypothyroidism, hyperthyroidism and thyroiditis occurred in patients receiving tremelimumab in combination with durvalumab and hypothyroidism may follow hyperthyroidism (see section 4.8). Patients should be monitored for abnormal thyroid function tests prior to and periodically during treatment and as indicated based on clinical evaluation. Immune-mediated hypothyroidism, hyperthyroidism, and thyroiditis should be managed as recommended<em> </em>in section 4.2.</p><p>&nbsp;</p><p><em><u>Immune-mediated adrenal insufficiency</u></em></p><p>Immune‑mediated adrenal insufficiency occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for clinical signs and symptoms of adrenal insufficiency. For symptomatic adrenal insufficiency, patients should be managed as recommended in section 4.2.</p><p>&nbsp;</p><p><em><u>Immune-mediated type 1 diabetes mellitus</u></em></p><p>Immune‑mediated type 1 diabetes mellitus, which can first present as diabetic ketoacidosis that can be fatal if not detected early, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for clinical signs and symptoms of type 1 diabetes mellitus. For symptomatic type 1 diabetes mellitus, occurred in patients receiving tremelimumab in combination with durvalumab (section 4.2.)</p><p>&nbsp;</p><p><em><u>Immune-mediated hypophysitis/hypopituitarism</u></em></p><p>Immune‑mediated hypophysitis or hypopituitarism occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for clinical signs and symptoms of hypophysitis or hypopituitarism. For symptomatic hypophysitis or hypopituitarism, patients should be managed as recommended in section 4.2.</p><p>&nbsp;</p><p><u>Immune‑mediated nephritis</u></p><p>Immune‑mediated nephritis, defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for abnormal renal function tests prior to and periodically during treatment and managed as recommended in section 4.2.</p><p>&nbsp;</p><p><u>Immune‑mediated rash</u></p><p>Immune‑mediated rash or dermatitis (including pemphigoid), defined as requiring use of systemic corticosteroids and with no clear alternate aetiology, occurred in patients receiving tremelimumab in combination with durvalumab see section 4.8). Events of Stevens-Johnson Syndrome or toxic epidermal necrolysis have been reported in patients treated with PD-1 and CTLA-4 inhibitors. Patients should be monitored for signs and symptoms of rash or dermatitis and managed as recommended in<em> </em>section 4.2.</p><p>&nbsp;</p><p><u>Immune-mediated myocarditis </u></p><p>Immune-mediated myocarditis, which can be fatal, occurred in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Patients should be monitored for signs and symptoms of immune-mediated myocarditis and managed as recommended in section 4.2.</p><p>&nbsp;</p><p><u>Other immune-mediated adverse reactions</u></p><p>Given the mechanism of action of tremelimumab in combination with durvalumab, other potential immune‑mediated adverse reactions may occur. The following immune-related adverse reactions have been observed in patients treated with tremelimumab in combination with durvalumab: myasthenia gravis, myositis, polymyositis, meningitis, encephalitis, Guillain‑Barr&eacute; syndrome, immune thrombocytopenia, cystitis noninfective and pancreatitis (see section 4.8). Patients should be monitored for signs and symptoms and managed as recommended in section 4.2.</p><p>&nbsp;</p><p><u>Infusion-related reactions</u></p><p>Patients should be monitored for signs and symptoms of infusion-related reactions. Severe infusion‑related reactions have been reported in patients receiving tremelimumab in combination with durvalumab (see section 4.8). Infusion-related reactions should be managed as recommended in section 4.2.</p><p>&nbsp;</p><p><u>Patients excluded from clinical studies</u></p><p>Patients with the following were excluded from clinical studies: Child-Pugh Score B or C, main portal vein thrombosis, liver transplant, uncontrolled hypertension, history of, or current brain metastases, spinal cord compression, co-infection of viral hepatitis B and hepatitis C, active or prior documented gastrointestinal (GI) bleeding within 12 months, ascites requiring non‑pharmacologic intervention within 6 months, hepatic encephalopathy within 12 months before the start of treatment, active or prior documented autoimmune or inflammatory disorders. In the absence of data, tremelimumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.</p><p>&nbsp;</p><p>Patients with the following were excluded from clinical studies: active or prior documented autoimmune disease; active and/or untreated brain metastases; a history of immunodeficiency; administration of systemic immunosuppression within 14&nbsp;days before the start of tremelimumab or durvalumab, except physiological dose of systemic corticosteroids (<u>&lt;</u>&nbsp;10&nbsp;mg/day prednisone or equivalent); uncontrolled intercurrent illness; active tuberculosis or hepatitis B or C or HIV infection or patients receiving live attenuated vaccine within 30 days before or after the start of tremelimumab or durvalumab. In the absence of data, tremelimumab should be used with caution in these populations after careful consideration of the potential benefit/risk on an individual basis.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of systemic corticosteroids or immunosuppressants before starting tremelimumab, except physiological dose of systemic corticosteroids (&le;&nbsp;10&nbsp;mg/day prednisone or equivalent), is not recommended because of their potential interference with the pharmacodynamic activity and efficacy of tremelimumab. However, systemic corticosteroids or other immunosuppressants can be used after starting tremelimumab to treat immune‑related adverse reactions (see section 4.4).</p><p>&nbsp;</p><p>No formal pharmacokinetic (PK) drug‑drug interaction studies have been conducted with tremelimumab. Since the primary elimination pathways of tremelimumab are protein catabolism via reticuloendothelial system or target‑mediated disposition, no metabolic drug-drug interactions are expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception</u></p><p>Women of childbearing potential should use effective contraception during treatment with tremelimumab and for at least 3 months after the last dose of tremelimumab.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no data on the use of tremelimumab in pregnant women. Based on its mechanism of action, tremelimumab has the potential to impact maintenance of pregnancy and may cause foetal harm when administered to a pregnant woman. In animal reproduction studies, administration of tremelimumab to pregnant cynomolgus monkeys during the period of organogenesis was not associated with maternal toxicity or any effects on maintenance of pregnancy or embryofoetal development (see section 5.3). Human IgG2 is known to cross the placental barrier. Tremelimumab is not recommended during pregnancy and in women of childbearing potential not using effective contraception during treatment and for at least 3 months after the last dose.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There is no information regarding the presence of tremelimumab in human milk, the absorption and effects on the breast-fed infant, or the effects on milk production. Human IgG2 is excreted in human milk. Because of the potential for adverse reactions from tremelimumab in breast-fed infants, breast-feeding women are advised not to breast-feed during treatment and for at least 3 months after the last dose.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no data on the potential effects of tremelimumab on fertility in humans or animals. However, mononuclear cell infiltration in prostate and uterus was observed in repeat-dose toxicity studies (see Section 5.3). The clinical relevance of these findings for fertility is unknown.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tremelimumab has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The safety of tremelimumab 300&nbsp;mg as a single dose in combination with durvalumab, is based on pooled data in 462 HCC patients (HCC pool) from the HIMALAYA Study and another study in HCC patients, Study 22. The most common (&gt;&nbsp;10%) adverse reactions were rash (32.5%), pruritus (25.5%), diarrhoea (25.3%), abdominal pain (19.7%), aspartate aminotransferase increased/alanine aminotransferase increased (18.0%), pyrexia (13.9%), hypothyroidism (13.0%), cough/productive cough (10.8%), oedema peripheral (10.4%) and lipase increased (10.0%) (see Table 4).</p><p>&nbsp;</p><p>The most common severe adverse reactions (NCI CTCAE Grade &ge;&nbsp;3) are aspartate aminotransferase increased/alanine aminotransferase increased (8.9%), lipase increased (7.1%), amylase increased (4.3%) and diarrhoea (3.9%).</p><p>&nbsp;</p><p>The most common serious adverse reactions are colitis (2.6%), diarrhoea (2.4%), pneumonia (2.2%), and hepatitis (1.7%).</p><p>&nbsp;</p><p>The frequency of treatment discontinuation due to adverse reactions is 6.5%. The most common adverse reactions leading to treatment discontinuation are hepatitis (1.5%) and aspartate aminotransferase increased/alanine aminotransferase increased (1.3%).</p><p>&nbsp;</p><p>The severity of adverse drug reactions was assessed based on the CTCAE, defining grade 1=mild, grade 2=moderate, grade 3=severe, grade 4=life threatening and grade 5=death.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Table 4, unless otherwise stated, lists the incidence of adverse reactions (ADRs) in patients treated with tremelimumab 300&nbsp;mg in combination with durvalumab in the HCC pool of 462 patients. Adverse reactions are listed according to system organ class in MedDRA. Within each system organ class, the ADRs are presented in decreasing frequency. The corresponding frequency category for each ADR is defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1000); very rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from available data). Within each frequency grouping, ADRs are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Table 4. Adverse reactions in patients with HCC treated with </strong>tremelimumab<strong> 300&nbsp;mg in combination with durvalumab</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:98%"><thead><tr><td><p><strong>&nbsp;</strong></p></td><td colspan="4" style="vertical-align:top"><p>Tremelimumab<strong> 300&nbsp;mg in combination with durvalumab</strong></p><p><strong>(n=462) </strong></p><p><strong>&nbsp;</strong></p></td></tr><tr><td><p><strong>Adverse Reaction</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Frequency of any Grade</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Frequency of Grade 3-4</strong></p></td></tr></thead><tbody><tr><td><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infections<sup>a</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>39 (8.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonia<sup>b</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>20 (4.3%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (1.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Influenza</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>10 (2.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dental and oral soft tissue infections<sup>c</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (1.3%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Oral candidiasis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>3 (0.6%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune thrombocytopenia<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Endocrine disorders</strong></p></td></tr><tr><td><p>Hypothyroidism<sup>e</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>60 (13.0%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Hyperthyroidism<sup>f</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>44 (9.5%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Thyroiditis<sup>g</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>8 (1.7%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Adrenal insufficiency</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (1.3%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td><p>Hypopituitarism/Hypophysitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>4 (0.9%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Diabetes insipidus<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Type 1 diabetes mellitus<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Myasthenia gravis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>2 (0.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Meningitis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Guillain-Barr&eacute; syndrome<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Encephalitis<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td><p>Myocarditis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>2 (0.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cough/Productive cough</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>50 (10.8%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Pneumonitis<sup>h</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>11 (2.4%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Dysphonia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>4 (0.9%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial lung disease</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>117 (25.3%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>18 (3.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain<sup>i</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>91 (19.7%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>10 (2.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Lipase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>46 (10.0%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>33 (7.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Amylase increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>41 (8.9%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>20 (4.3%)</p></td></tr><tr><td style="vertical-align:top"><p>Colitis<sup>j</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>16 (3.5%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>12 (2.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis<sup>k</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (1.3%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>3 (0.6%)</p></td></tr><tr><td style="vertical-align:top"><p>Intestinal perforation<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Large intestine perforation<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased/Alanine aminotransferase increased<sup>l</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>83 (18.0%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>41 (8.9%)</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis<sup>m</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>23 (5.0%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>8 (1.7%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>n</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>150 (32.5%)</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>14 (3.0%)</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>118 (25.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dermatitis<sup>o</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (1.3%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Night sweats</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (1.3%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pemphigoid</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>16 (3.5%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Myositis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>3 (0.6%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Polymyositis</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>21 (4.5%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>2 (0.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Dysuria</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>7 (1.5%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nephritis<sup>p</sup></p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>3 (0.6%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>2 (0.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Cystitis noninfective<sup>d</sup></p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>64 (13.9%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>1 (0.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Oedema peripheral<sup>q</sup></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>48 (10.4%)</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>2 (0.4%)</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infusion-related reaction<sup>r</sup></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>6 (1.3%)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a </sup>Includes nasopharyngitis, pharyngitis, rhinitis, tracheobronchitis and upper respiratory tract infection.</p><p><sup>b</sup> Includes pneumocystis jirovecii pneumonia and pneumonia.</p><p><sup>c</sup> Includes periodontitis, pulpitis dental, tooth abscess and tooth infection.</p><p><sup>d</sup> Adverse reaction was not observed in the HCC pool, but was reported in patients treated with durvalumab or durvalumab + tremelimumab in AstraZeneca-sponsored clinical studies.</p><p><sup>e</sup> Includes blood thyroid stimulating hormone increased, hypothyroidism and immune-mediated hypothyroidism.</p><p><sup>f</sup> Includes blood thyroid stimulating hormone decreased and hyperthyroidism.</p><p><sup>g </sup>Includes autoimmune thyroiditis, immune-mediated thyroiditis, thyroiditis and thyroiditis subacute.</p><p><sup>h</sup> Includes immune-mediated pneumonitis and pneumonitis.</p><p><sup>i </sup>Includes abdominal pain, abdominal pain lower, abdominal pain upper and flank pain.</p><p><sup>j </sup>Includes colitis, enteritis and enterocolitis.</p><p><sup>k</sup> Includes pancreatitis and pancreatitis acute.</p><p><sup>l </sup>Includes alanine aminotransferase increased, aspartate aminotransferase increased, hepatic enzyme increased and transaminases increased.</p><p><sup>m </sup>Includes autoimmune hepatitis, hepatitis, hepatocellular injury, hepatotoxicity and immune-mediated hepatitis.</p><p><sup>n</sup> Includes eczema, erythema, rash, rash macular, rash maculo-papular, rash papular and rash pruritic.</p><p><sup>o </sup>Includes dermatitis and immune-mediated dermatitis.</p><p><sup>p</sup> Includes autoimmune nephritis and immune-mediated nephritis.</p><p><sup>q </sup>Includes oedema peripheral and peripheral swelling.</p><p><sup>r</sup> Includes infusion-related reaction and urticaria.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>The data below reflects information for significant adverse reactions for tremelimumab 300&nbsp;mg in combination with durvalumab in the HCC pool (n=462).</p><p>&nbsp;</p><p><em><u>Immune‑mediated pneumonitis</u></em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune‑mediated pneumonitis occurred in 86 (3.8%) patients, including Grade 3 in 30 (1.3%) patients, Grade 4 in 1 (&lt;&nbsp;0.1%) patient, and Grade 5 (fatal) in 7 (0.3%) patients. The median time to onset was 57 days (range: 8&nbsp;-&nbsp;912 days). All patients received systemic corticosteroids and 79 of the 86 patients received high‑dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Seven patients also received other immunosuppressants. Treatment was discontinued in 39 patients. Resolution occurred in 51 patients.</p><p>&nbsp;</p><p>In the HCC pool (n=462), immune‑mediated pneumonitis occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient and Grade 5 (fatal) in 1 (0.2%) patient. The median time to onset was 29 days (range: 5-774 days). Six patients received systemic corticosteroids, and 5 of the 6 patients received high‑dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). One patient also received other immunosuppressants. Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.</p><p>&nbsp;</p><p><em><u>Immune‑mediated hepatitis</u></em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune‑mediated hepatitis occurred in 80 (3.5%) patients, including Grade 3 in 48 (2.1%) patients, Grade 4 in 8 (0.4%) patients and Grade 5 (fatal) in 2 (&lt;&nbsp;0.1%) patients. The median time to onset was 36 days (range: 1&nbsp;-&nbsp;533 days). All patients received systemic corticosteroids and 68 of the 80 patients received high‑dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Eight patients also received other immunosuppressants. Treatment was discontinued in 27 patients. Resolution occurred in 47 patients.</p><p>&nbsp;</p><p>In the HCC pool (n=462), immune‑mediated hepatitis occurred in 34 (7.4%) patients, including Grade 3 in 20 (4.3%) patients, Grade 4 in 1 (0.2%) patient and Grade 5 (fatal) in 3 (0.6%) patients. The median time to onset was 29 days (range: 13-313 days). All patients received systemic corticosteroids, and 32 of the 34 patients received high‑dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Nine patients also received other immunosuppressants. Treatment was discontinued in 10 patients. Resolution occurred in 13 patients.</p><p>&nbsp;</p><p><em><u>Immune‑mediated colitis</u></em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune‑mediated colitis or diarrhoea occurred in 167 (7.3%) patients, including Grade 3 in 76 (3.3%) patients and Grade 4 in 3 (0.1%) patients. The median time to onset was 57 days (range: 3&nbsp;-&nbsp;906 days). All patients received systemic corticosteroids and 151 of the 167 patients received high‑dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Twenty-two patients also received other immunosuppressants. Treatment was discontinued in 54 patients. Resolution occurred in 141 patients.</p><p>&nbsp;</p><p>Intestinal perforation and large intestine perforation were uncommonly reported in patients receiving tremelimumab in combination with durvalumab.</p><p>In the HCC pool (n=462), immune‑mediated colitis or diarrhoea occurred in 31 (6.7%) patients, including Grade 3 in 17 (3.7%) patients. The median time to onset was 23 days (range: 2-479 days). All patients received systemic corticosteroids, and 28 of the 31 patients received high‑dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Four patients also received other immunosuppressants. Treatment was discontinued in 5 patients. Resolution occurred in 29 patients.</p><p>&nbsp;</p><p>Intestinal perforation was observed in patients receiving tremelimumab in combination with durvalumab (rare) in studies outside of the HCC pool.</p><p>&nbsp;</p><p><em><u>Immune‑mediated endocrinopathies</u></em></p><p>&nbsp;</p><p><em>Immune-mediated hypothyroidism</em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune-mediated hypothyroidism occurred in 209 (9.2%) patients, including Grade 3 in 6 (0.3%) patients. The median time to onset was 85 days (range: 1&nbsp;-&nbsp;624 days). Thirteen patients received systemic corticosteroids and 8 of the 13 received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Treatment discontinued in 3 patients. Resolution occurred in 52 patients.</p><p>&nbsp;</p><p>In the HCC pool (n=462), immune-mediated hypothyroidism occurred in 46 (10.0%) patients. The median time to onset was 85 days (range: 26-763 days). One patient received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). All patients required other therapyincluding hormone replacement therapy . Resolution occurred in 6 patients. Immune-mediated hypothyroidism was preceded by immune-mediated hyperthyroidism in 4 patients .</p><p><em>&nbsp;</em></p><p><em>Immune-mediated hyperthyroidism</em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune-mediated hyperthyroidism occurred in 62 (2.7%) patients, including Grade 3 in 5 (0.2%) patients. The median time to onset was 33 days (range: 4&nbsp;-&nbsp;176 days). Eighteen patients received systemic coticosteroids, and 11 of the 18 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Fifty-three patients required other therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker or beta-blocker), One patient discontinued treatment due to hyperthyroidism. Resolution occurred in 47 patients.</p><p>&nbsp;</p><p>In the HCC pool (n=462), immune-mediated hyperthyroidism occurred in 21 (4.5%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 30 days (range: 13-60 days). Four patients received systemic corticosteriods, and all of the four patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Twenty patients required other therapy (thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker). One patient discontinued treatment due to hyperthyroidism. Resolution occurred in 17 patients.</p><p>&nbsp;</p><p><em>Immune-mediated thyroiditis</em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune-mediated thyroiditis occurred in 15 (0.7%) patients, including Grade 3 in 1 (&lt;&nbsp;0.1%) patient. The median time to onset was 57 days (range: 22&nbsp;-&nbsp;141 days). Five patients received systemic corticosteroids and 2 of the 5 patients received high-dose corticosteroid treatment (at least 40 mg prednisone or equivalent per day). Thirteen patients required other therapy including, hormone replacement therapy, thiamazole, carbimazole, propylthiouracil, perchlorate, calcium channel blocker, or beta-blocker. No patients discontinued treatment due to immune-mediated thyroiditis. Resolution occurred in 5 patients.</p><p>&nbsp;</p><p>In the HCC pool (n=462), immune-mediated thyroiditis occurred in 6 (1.3%) patients. The median time to onset was 56 days (range: 7-84 days). Two patients received systemic corticosteroids, and 1 of the 2 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). All patients required other therapy including hormone replacement therapy. Resolution occurred in 2 patients.</p><p>&nbsp;</p><p><em>Immune-mediated adrenal insufficiency</em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune-mediated adrenal insufficiency occurred in 33 (1.4%) patients, including Grade 3 in 16 (0.7%) patients and Grade 4 in 1 (&lt;&nbsp;0.1%) patient. The median time to onset was 105 days (range: 20-428 days). Thirty-two patients received systemic corticosteroids, and 10 of the 32 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Treatment was discontinued in one patient. Resolution occurred in 11 patients.</p><p>In the HCC pool (n=462), immune-mediated adrenal insufficiency occurred in 6 (1.3%) patients, including Grade 3 in 1 (0.2%) patient. The median time to onset was 64 days (range: 43-504 days). All patients received systemic corticosteroids, and 1 of the 6 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Resolution occurred in 2 patients.</p><p>&nbsp;</p><p><em>Immune-mediated type 1 diabetes mellitus</em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune-mediated type 1 diabetes mellitus occurred in 6 (0.3%) patients, including Grade 3 in 1 (&lt;&nbsp;0.1%) patient and Grade 4 in 2 (&lt;&nbsp;0.1%) patients. The median time to onset was 58 days (range: 7&nbsp;-&nbsp;220 days). All patients required insulin. Treatment was discontinued for 1 patient. Resolution occurred in 1 patient.</p><p>Immune-mediated type 1 diabetes mellitus was observed in patients receiving tremelimumab in combination with durvalumab (uncommon) in studies outside of the HCC pool.</p><p>&nbsp;</p><p><em>Immune-mediated hypophysitis/hypopituitarism</em></p><p>In the HCC pool (n=462), immune-mediated hypophysitis/hypopituitarism occurred in 5 (1.1%) patients. The median time to onset for the events was 149 days (range: 27-242 days). Four patients received systemic corticosteroids, and 1 of the 4 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Three patients also required endocrine therapy. Resolution occurred in 2 patients.</p><p>&nbsp;</p><p><em><u>Immune‑mediated nephritis </u></em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune-mediated hypophysitis/hypopituitarism occurred in 16 (0.7%) patients, including Grade 3 in 8 (0.4%) patients. The median time to onset for the events was 123 days (range: 63&nbsp;-&nbsp;388 days). All patients received systemic corticosteroids and 8 of the 16 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Four patients also required endocrine therapy. Treatment was discontinued in 2 patients. Resolution occurred in 7 patients.</p><p>&nbsp;</p><p>In the HCC pool (n=462), immune-mediated nephritis occurred in 4 (0.9%) patients, including Grade 3 in 2 (0.4%) patients. The median time to onset was 53 days (range: 26-242 days). All patients received systemic corticosteroids, and 3 of the 4 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Treatment was discontinued in 2 patients. Resolution occurred in 3 patients.</p><p>&nbsp;</p><p><em><u>Immune‑mediated rash</u></em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, immune-mediated rash or dermatitis (including pemphigoid) occurred in 112 (4.9%) patients, including Grade 3 in 17 (0.7%) patients. The median time to onset was 35 days (range: 1&nbsp;-&nbsp;778 days). All patients received systemic corticosteroids, and 57 of the 112 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). Treatment was discontinued in 10 patients. Resolution occurred in 65 patients.</p><p>&nbsp;</p><p>In the HCC pool (n=462), immune-mediated rash or dermatitis (including pemphigoid) occurred in 26 (5.6%) patients, including Grade 3 in 9 (1.9%) patients and Grade 4 in 1 (0.2%) patient. The median time to onset was 25 days (range: 2-933 days). All patients received systemic corticosteroids and 14 of the 26 patients received high-dose corticosteroid treatment (at least 40&nbsp;mg prednisone or equivalent per day). One patient received other immunosuppressants. Treatment was discontinued in 3 patients. Resolution occurred in 19 patients.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Infusion-related reactions</u></em></p><p>In the combined safety database with tremelimumab in combination with durvalumab, infusion-related reactions occurred in 45 (2.0%) patients,<sup> </sup>including Grade 3 in 2 (&lt;&nbsp;0.1%) patients. There were no Grade 4 or 5 events.</p><p>&nbsp;</p><p><u>Immunogenicity </u></p><p>&nbsp;</p><p>In the HIMALAYA study, of the 182 patients who were treated with tremelimumab 300&nbsp;mg as a single dose in combination with durvalumab and evaluable for the presence of ADAs against tremelimumab, 20 (11.0%) patients tested positive for treatment-emergent ADAs. Neutralising antibodies against tremelimumab were detected in 4.4% (8/182) patients. The presence of ADAs did not have an apparent effect on pharmacokinetics or safety. The presence of ADAs did not impact tremelimumab pharmacokinetics, and there was no apparent effect on efficacy and safety .</p><p>&nbsp;</p><p><u>Elderly</u></p><p>Data from &nbsp;HCC patients 75&nbsp;years of age or older are limited.</p><p>&nbsp;</p><p>&nbsp;</p><p>To report any side effect(s):</p><ul><li><strong><em>Saudi Arabia: </em></strong></li></ul><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p><p>- The National Pharmacovigilance Centre (NPC)</p><p>o&nbsp;&nbsp; Toll free phone: 19999</p><p>o&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa &nbsp;&nbsp;</p><p>o&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&middot;&nbsp;&nbsp; Other GCC States:</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no information on overdose with tremelimumab. In case of overdose, patients should be closely monitored for signs or symptoms of adverse reactions, and appropriate symptomatic treatment instituted immediately.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other monoclonal antibodies and antibody drug conjugates. ATC code: L01FX20</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Cytotoxic T lymphocyte-associated antigen (CTLA-4) is primarily expressed on the surface of T lymphocytes. Interaction of CTLA-4 with its ligands, CD80 and CD86, limits effector T-cell activation, through a number of potential mechanisms, but primarily by limiting co-stimulatory signalling through CD28.</p><p>&nbsp;</p><p>Tremelimumab is a selective, fully human IgG2 antibody that blocks CTLA-4 interaction with CD80 and CD86, thus enhancing T-cell activation and proliferation, resulting in increased T-cell diversity and enhanced antitumour activity.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Clinical efficacy</u></p><p><em><u>HCC - HIMALAYA Study</u></em></p><p>The efficacy of IMJUDO 300&nbsp;mg as a single dose in combination with durvalumab was evaluated in the HIMALAYA Study, a randomised, open-label, multicentre study in patients with confirmed uHCC who did not receive prior systemic treatment for HCC. The study included patients with Barcelona Clinic Liver Cancer (BCLC) Stage C or B (not eligible for locoregional therapy) and Child-Pugh Score Class A.</p><p>&nbsp;</p><p>The study excluded patients with brain metastases or a history of brain metastases, co-infection of viral hepatitis B and hepatitis C; active or prior documented gastro-intestinal (GI) bleeding within 12 months; ascites requiring non-pharmacologic intervention within 6 months; hepatic encephalopathy within 12 months before the start of treatment; active or prior documented autoimmune or inflammatory disorders.</p><p>&nbsp;</p><p>Patients with esophageal varices were included except those with active or prior documented GI bleeding within 12 months prior to study entry.</p><p>&nbsp;</p><p>Randomisation was stratified by macrovascular invasion (MVI) (yes vs. no), aetiology of liver disease (confirmed hepatitis B virus vs. confirmed hepatitis C virus vs. others) and ECOG performance status (0 vs. 1). The HIMALAYA study randomized 1171 patients 1:1:1 to receive:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; D: durvalumab 1500&nbsp;mg every 4 weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IMJUDO 300&nbsp;mg as a single dose + durvalumab 1500&nbsp;mg; followed by durvalumab 1500&nbsp;mg every 4 weeks</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; S: Sorafenib 400&nbsp;mg twice daily</p><p>&nbsp;</p><p>Tumour assessments were conducted every 8 weeks for the first 12 months and then every 12 weeks thereafter. Survival assessments were conducted every month for the first 3 months following treatment discontinuation and then every 2 months.</p><p>&nbsp;</p><p>The primary endpoint was Overall Survival (OS). Secondary endpoints included Progression-Free Survival (PFS), Investigator-assessed Objective Response Rate (ORR) and Duration of Response (DoR) according to RECIST v1.1.</p><p>&nbsp;</p><p>The demographics and baseline disease characteristics were well balanced between study arms. The baseline demographics of the overall study population were as follows: male (83.7%), age &lt;&nbsp;65 years (50.4%) White (44.6%), Asian (50.7%), Black or African American (1.7%), Other race (2.3%), ECOG PS 0 (62.6%); Child-Pugh Class score A (99.5%), macrovascular invasion (25.2%), extrahepatic spread (53.4%), baseline AFP &lt;&nbsp;400&nbsp;ng/ml (63.7%), baseline AFP &ge;&nbsp;400&nbsp;ng/ml (34.5%), viral aetiology; hepatitis B (30.6%), hepatitis C (27.2%), uninfected (42.2%), evaluable PD-L1 data (86.3%), PD-L1 Tumour area positivity (TAP) &ge;&nbsp;1% (38.9%), PD-L1 TAP &lt;&nbsp;1% (48.3%) [Ventana PD-L1 (SP263) assay].</p><p>&nbsp;</p><p>Results are presented in Table 5 and Figure 1.</p><p>&nbsp;</p><p><strong>Table 5. Efficacy Results for the HIMALAYA Study for IMJUDO 300&nbsp;mg with durvalumab vs. S </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>IMJUDO&nbsp;300&nbsp;mg + durvalumab</strong></p><p><strong>(n=</strong><strong> </strong><strong>393</strong><strong>)</strong></p></td><td style="vertical-align:top"><p><strong>S</strong></p><p><strong>(n=</strong><strong> </strong><strong>389</strong><strong>)</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Follow-up duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>Median follow-up (months)<sup>a</sup></p></td><td style="vertical-align:top"><p>33.2</p></td><td style="vertical-align:top"><p>32.2</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>OS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of deaths (%)</p></td><td style="vertical-align:top"><p>262 (66.7)</p></td><td style="vertical-align:top"><p>293 (75.3)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Median OS (months)</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>16.4</strong></p><p><strong>(14.2, 19.6)</strong></p></td><td style="vertical-align:top"><p><strong>13.8</strong></p><p><strong>(12.3, 16.1)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>HR (95% CI)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>0.78 (0.66, 0.92)</strong></p></td></tr><tr><td style="vertical-align:top"><p>p-value<sup>b</sup></p></td><td colspan="2" style="vertical-align:top"><p>0.0035</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>PFS</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>335 (85.2)</p></td><td style="vertical-align:top"><p>327 (84.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Median PFS (months) </strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>3.78 </strong></p><p><strong>(3.68, 5.32)</strong></p></td><td style="vertical-align:top"><p><strong>4.07 </strong></p><p><strong>(3.75, 5.49)</strong></p></td></tr><tr><td style="vertical-align:top"><p>HR (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.90 (0.77, 1.05)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>ORR</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>ORR n (%)<sup>c</sup> </strong></p></td><td style="vertical-align:top"><p>79 (20.1)</p></td><td style="vertical-align:top"><p>20 (5.1)</p></td></tr><tr><td style="vertical-align:top"><p>Complete Response n (%)</p></td><td style="vertical-align:top"><p>12 (3.1)</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>Partial Response n (%)</p></td><td style="vertical-align:top"><p>67 (17.0)</p></td><td style="vertical-align:top"><p>20 (5.1)</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>DoR</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Median DoR (months) </strong></p></td><td style="vertical-align:top"><p>22.3</p></td><td style="vertical-align:top"><p>18.4</p></td></tr></tbody></table><p><sup>a</sup> Calculated using reverse the Kaplan-Meier technique (with censor indicator reversed).</p><p><sup>b </sup>Based on a Lan-DeMets alpha spending function with O&#39;Brien Fleming type boundary and the actual number of events observed, the boundary for declaring statistical significance for IMJUDO 300&nbsp;mg + durvalumab vs. S was 0.0398 (Lan◦and◦DeMets 1983).</p><p><sup>c</sup> Confirmed complete response.</p><p>NR=Not Reached, CI=Confidence Interval</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>Figure 1. Kaplan-Meier curve of OS</strong></p><p><img src="data:image/jpeg;base64,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" alt="" width="1390" height="741" vspace="0" hspace="0" border="0" style="width:1390px;height:741px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p><p><u>Paediatric population </u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with tremelimumab in all subsets of the paediatric population in the treatment of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms). See section 4.2 for information on paediatric use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics (PK) of tremelimumab was assessed for tremelimumab as monotherapy and in combination with durvalumab.</p><p>&nbsp;</p><p>The PK of tremelimumab was studied in patients with doses ranging from 75&nbsp;mg to 750&nbsp;mg or 10&nbsp;mg/kg administered intravenously once every 4 or 12 weeks as monotherapy, or at a single dose of 300&nbsp;mg. PK exposure increased dose proportionally (linear PK) at doses &ge;&nbsp;75&nbsp;mg. Steady state was achieved at approximately 12 weeks. Based on population PK analysis that included patients who received tremelimumab monotherapy or in combination with other medicinal products in the dose range of &ge;&nbsp;75&nbsp;mg (or 1&nbsp;mg/kg) every 3 or 4 weeks, the estimated tremelimumab clearance (CL) and volume of distribution (Vd) were 0.309&nbsp;l/day and 6.33&nbsp;l, respectively. The terminal half-life was approximately 14.2<s> </s>days. The primary elimination pathways of tremelimumab are protein catabolism via reticuloendothelial system or target mediated disposition.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>For HIMALAYA:</p><p>Age (22&nbsp;-&nbsp;97 years), body weight (34&nbsp;-&nbsp;149&nbsp;kg), gender, positive anti-drug antibody (ADA) status, albumin levels, LDH levels, creatinine levels, tumour type, race or ECOG/WHO status had no clinically significant effect on the PK of tremelimumab.</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p>Mild (creatinine clearance (CrCL) 60 to 89&nbsp;ml/min) and moderate renal impairment (creatinine clearance (CrCL) 30 to 59&nbsp;ml/min) had no clinically significant effect on the PK of tremelimumab. The effect of severe renal impairment (CrCL 15 to 29&nbsp;ml/min) on the PK of tremelimumab is unknown. the potential need for dose adjustment cannot be determined. However, as IgG monoclonal antibodies are not primarily cleared via renal pathways, a change in renal function is not expected to influence tremelimumab exposure.</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u></p><p>&nbsp;</p><p>Mild hepatic impairment (bilirubin &le;&nbsp;ULN and AST &gt;&nbsp;ULN or bilirubin &gt;&nbsp;1.0 to 1.5&nbsp;&times;&nbsp;ULN and any AST) had no clinically significant effect on the PK of tremelimumab. The effect of moderate hepatic impairment (bilirubin &gt;&nbsp;1.5 to 3&nbsp;x&nbsp;ULN and any AST) or severe hepatic impairment (bilirubin &gt;&nbsp;3.0&nbsp;x&nbsp;ULN and any AST) on the PK of tremelimumab is unknown; the potential need for dose adjustment cannot be determined. However, as IgG monoclonal antibodies are not primarily cleared via hepatic pathways, a change in hepatic function is not expected to influence tremelimumab exposure.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Animal toxicology</u></p><p>&nbsp;</p><p>In the chronic 6-month study in cynomolgus monkeys, treatment with tremelimumab was associated with dose-related incidence in persistent diarrhoea and skin rash, scabs and open sores, which were dose-limiting. These clinical signs were also associated with decreased appetite and body weight and swollen peripheral lymph nodes. Histopathological findings correlating with the observed clinical signs included reversible chronic inflammation in the cecum and colon, mononuclear cell infiltration in the skin and hyperplasia in lymphoid tissues.</p><p>&nbsp;</p><p>For HIMALAYA:</p><p>&nbsp;</p><p>A dose-dependent increase in the incidence and severity of mononuclear cell infiltration with or without mononuclear cell inflammation was observed in the salivary gland, pancreas (acinar), thyroid, parathyroid, adrenal, heart, esophagus, tongue, periportal liver area, skeletal muscle, prostate, uterus, pituitary, eye (conjunctiva, extra ocular muscles), and choroid plexus of the brain. No NOAEL was found in this study with animals treated with the lowest dose of 5&nbsp;mg/kg/week requiring supportive care. This dose provided an exposure-based safety margin of 3 to clinical relevant exposure (taking species difference in potency into account).</p><p>&nbsp;</p><p><u>Carcinogenicity and mutagenicity</u></p><p>&nbsp;</p><p>The carcinogenic and genotoxic potential of tremelimumab has not been evaluated.</p><p>&nbsp;</p><p><u>Reproductive toxicology</u></p><p>Animal fertility studies have not been conducted with tremelimumab. Mononuclear cell infiltration in prostate and uterus was observed in repeat dose toxicity studies. Since animal fertility studies have not been conducted with tremelimumab, the clinical relevance of these findings for fertility is unknown. In reproduction studies, administration of tremelimumab to pregnant cynomolgus monkeys during the period of organogenesis was not associated with maternal toxicity or effects pregnancy losses, foetal weights, or external, visceral, skeletal abnormalities or weights of selected foetal organs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Histidine</p><p>Histidine hydrochloride monohydrate</p><p>Trehalose dihydrate</p><p>Disodium edetate dihydrate</p><p>Polysorbate 80</p><p>Water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened vial

4 years at 2 °C - 8 °C.

Diluted solution

Chemical and physical in-use stability has been demonstrated for up to 28 days at 2 °C to 8 °C and for up to 48 hours at room temperature (up to 25 °C) from the time of preparation.  
 
From a microbiological point of view, the prepared solution for infusion should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 °C to 8 °C or 12 hours at room temperature (up to 25 °C), unless dilution has taken place in controlled and validated aseptic conditions.

Lack of microbial growth in the prepared solution for infusion has been demonstrated for up to 28 days at 2 °C to 8 °C and for up to 48 hours at room temperature (up to 25 °C) from the time of preparation. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&deg;C&nbsp;-&nbsp;8&nbsp;&deg;C).</p><p>&nbsp;</p><p>Do not freeze.</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after dilution of the medicinal product, see section 6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Two pack sizes of IMJUDO are available:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.25&nbsp;ml (a total of 25&nbsp;mg tremelimumab) concentrate in a Type I glass vial with an elastomeric stopper and a violet flip-off aluminum seal. Pack size of 1 single-dose vial.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15&nbsp;ml (a total of 300&nbsp;mg tremelimumab) concentrate in a Type I glass vial with an elastomeric stopper and a dark blue flip-off aluminum seal. Pack size of 1 single-dose vial.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Preparation of solution</u></p><p>IMJUDO is supplied as a single-dose vial and does not contain any preservatives, aseptic technique must be observed.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Visually inspect medicinal product for particulate matter and discolouration. IMJUDO is clear to slightly opalescent, colourless to slightly yellow solution. Discard the vial if the solution is cloudy, discoloured or visible particles are observed. Do not shake the vial.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Withdraw the required volume from the vial(s) of IMJUDO and transfer into an intravenous bag containing sodium chloride 9&nbsp;mg/ml (0.9%) solution for injection, or glucose 50&nbsp;mg/ml (5%) solution for injection. Mix diluted solution by gentle inversion. The final concentration of the diluted solution should be between 0.1&nbsp;mg/&nbsp;ml and 10&nbsp;mg/ml. Do not freeze or shake the solution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Care must be taken to ensure the sterility of the prepared solution.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not re-enter the vial after withdrawal of the medicinal product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Discard any unused portion left in the vial.</p><p>&nbsp;</p><p><u>Administration</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Administer the infusion solution intravenously over 60 minutes through an intravenous line containing a sterile, low-protein binding 0.2 or 0.22&nbsp;micron in-line filter.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not co-administer other medicinal products through the same infusion line.</p><p>&nbsp;</p><p>Disposal</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                AstraZeneca AB
SE 151 85 Södertälje
Sweden

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Last update was 23 Feb 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>